March 10th 2023
EMBL-EBI researchers use UK Biobank data to uncover new information about rare diseases of the eye.
Gene therapy helps patient with retinitis pigmentosa achieve partial vision
May 26th 2021An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.
Treatment with voretigene neparvovec-rzyl results in foveal morphologic changes in LCA
May 10th 2021In a presentation at ARVO, Friederike Kortuem, MD, MSc, explains that treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.
Initial data from AGTC-501 subretinal gene therapy for X-linked RP demonstrates safety, efficacy
May 5th 2021During an ARVO presentation, Paul Yang, MD, PhD, explained that in a clinical trial, investigators used an adeno-associated viral vector to deliver a normal functioning copy of the RPGR gene via subretinal injection.
Non-viral gene therapy eases treatment burden in wet AMD
May 3rd 2021EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.
Investigators find genetic factors may influence diabetic eye disease
March 1st 2021Study results, including data from approximately 42,000 eyes, found diabetic retinopathy severity is a risk factor for diabetic eye disease progression. Other findings support the idea that genetic factors may influence the development of proliferative diabetic retinopathy versus diabetic macular oedema.
Investigators explore pathogenic cytokines as biomarkers for DMO
January 27th 2021Results of a study analysing cytokine levels in the aqueous humour and serum of patients with nonproliferative diabetic retinopathy with and without diabetic macular oedema support further research investigating transforming growth factor-β-induced Gene Human Clone 30 (BIGH3) as a potential biomarker for DMO.